Creating highly effective antibodies for studying individual cells
Development of ultra-efficient antibodies for single cell mapping applications
This study is working on creating special antibodies that help scientists better understand how tiny changes in proteins called histones affect diseases, especially in rare cells, which could lead to new treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Epicypher, INC. NIH-funded |
| Lab location | 1 site (Research Triangle Park, UNITED STATES) |
| Project ID | NIH-11039937 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of antibodies designed to enhance the study of histone post-translational modifications (PTMs) in single cells. By utilizing a novel antibody development pipeline, the project aims to create ultra-efficient antibodies that can bind specifically to histone PTMs, which are crucial for understanding various diseases. The approach involves using a technique called CUT&Tag, which allows for genomic mapping with minimal cell input, making it possible to analyze rare cell populations. This could significantly improve drug discovery efforts by providing insights into the epigenetic landscape of diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diseases linked to alterations in histone PTMs, particularly those with rare or heterogeneous cell populations.
Not a fit: Patients with conditions unrelated to histone modifications or those not represented in single-cell analyses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments by enabling better understanding of disease mechanisms at the single-cell level.
How similar studies have performed: Previous research has shown promise in using antibody-mediated genomic mapping techniques, but the development of ultra-efficient antibodies for single-cell applications is a novel approach.
Where this research is happening
Research Triangle Park, UNITED STATES
- Epicypher, INC. — Research Triangle Park, United States (Active)
Researchers
- Principal investigator: Johnstone, Andrea Lynn — Epicypher, INC.
- Study coordinator: Johnstone, Andrea Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.